Suven Life Sciences Secures Patent
09 January 2007
Suven Life Sciences Ltd on January 09, 2007 has announced having received from the European Patent Office (EPO) issued a Patent titled "Novel Tetracyclic Arylcarbonylindoles having Serotonin Receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them" valid until June 2023.
The granted claims of the patent include the class of selective 5-HT compounds discovered by the company and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-degenarative disorders like attention deficient hyperactivity, Alzheimer's, Parkinson, schizophrenia and Huntington's.
"We continue to work on G-Protein coupled receptor (GPCR) targets to discover and develop molecules focusing on CNS disorders with unmet medical need and high market potential," said Venkat Jasti, CEO of the company.
Suven life Sciences is a major service provider of drug discovery and development support services (DDDSS) to global pharmaceutical, life sciences and biotech companies in addition to contract research and manufacturing services (CRAMS).